Antimicrobial resistance and characterisation of staphylococci isolated from healthy Labrador retrievers in the United Kingdom

Vanessa M Schmidt1,6*, Nicola J Williams2†, Gina Pinchbeck2†, Caroline E Corless3†, Stephen Shaw4†, Neil McEwan1,6†, Susan Dawson2† and Tim Nuttall5†

Abstract

Background: Coagulase-positive (CoPS) and coagulase-negative (CoNS) staphylococci are normal commensals of the skin and mucosa, but are also opportunist pathogens. Meticillin-resistant (MR) and multidrug-resistant (MDR) isolates are increasing in human and veterinary healthcare. Healthy humans and other animals harbour a variety of staphylococci, including MR-CoPS and MR-CoNS. The main aims of the study were to characterise the population and antimicrobial resistance profiles of staphylococci from healthy non-vet visiting and non-antimicrobial treated Labrador retrievers in the UK.

Results: Nasal and perineal samples were collected from 73 Labrador retrievers; staphylococci isolated and identified using phenotypic and biochemical methods. They were also confirmed by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF-MS), PCR of the nuc gene and PCR and sequencing of the tuf gene. Disc diffusion and minimum inhibitory concentration (MIC) susceptibility tests were determined for a range of antimicrobials. In total, 102 CoPS (S. pseudintermedius n = 91, S. aureus n = 11) and 334 CoNS isolates were detected from 99% of dogs in this study. In 52% of dogs CoNS only were detected, with both CoNS and CoPS detected in 43% dogs and CoPS only detected in 4% of dogs. Antimicrobial resistance was not common among CoPS, but at least one MDR-CoNS isolate was detected in 34% of dogs. MR-CoNS were detected from 42% of dogs but no MR-CoPS were isolated. S. epidermidis (52% of dogs) was the most common CoNS found followed by S. warneri (30%) and S. equorum (27%), with another 15 CoNS species isolated from ≤15% of dogs. S. pseudintermedius and S. aureus were detected in 44% and 8% of dogs respectively.

Conclusions: MR- and MDR-CoPS were rare. However a high prevalence of MR- and MDR-CoNS were found in these dogs, even though they had no prior antimicrobial treatment or admission to veterinary premises. These findings are of concern due to the potential for opportunistic infections, zoonotic transmission and transmission of antimicrobial resistant determinants from these bacteria to coagulase positive staphylococci.

Keywords: Coagulase-positive staphylococci, Coagulase-negative staphylococci, Meticillin-resistant, Dogs, MALDI-TOF-MS, Tuf gene, Nuc gene, Antimicrobial-susceptibility
Background

Staphylococci are normal commensal bacteria of the skin and mucous membranes of humans and other animals. They can be differentiated by their ability to produce coagulase, with coagulase positive (CoPS) staphylococci regarded as more pathogenic than coagulase negative (CoNS) species [1-5].

Healthy humans and other animals may harbour multiple species and strains of staphylococci. *Staphylococcus aureus* is the main human commensal CoPS species and is carried in the nasal cavity of approximately 30% of healthy people [6]. *S. epidermidis* is the most common CoNS isolated from the nares, perineum, inguinal skin, axillae and interdigital skin in man [2,7]. The main commensal CoPS of dogs, *S. pseudintermedius* [8], has been isolated from 37% to 92% of healthy dogs [9-14], while *S. aureus* is carried by 4.3% to 12% of healthy dogs [10,12,15-20]. Other species isolated from the mucosa and skin of healthy dogs include the CoPS *S. schleiferi* subspecies *coagulans* [10,21] and numerous CoNS (*S. schleiferi* subspecies *schleiferi*, *S. epidermidis*, *S. haemolyticus*, *S. saprophyticus*, *S. devriesii*, *S. warneri*, *S. simulans*, *S. xylosus*, *S.capitus*, *S. caprae*, and *S. sciuri*) [12,15,22-26]. The carriage rate of CoNS isolated from the nasal mucosa of healthy dogs was reported to be 38% in one large cross-sectional study [15].

Staphylococci are frequent opportunistic pathogens and commensal isolates are the most common source of infection in humans [3] and dogs [12,16,27]. Antimicrobial resistance can increase the morbidity, mortality and treatment cost of staphylococcal infections. Meticillin (oxacillin) resistance associated with carriage of the *mec* gene confers resistance to all β-lactam antimicrobials [28]. The *mecA* gene is located on a large mobile genetic element, the staphylococcal cassette chromosome mec (SCCmec), enabling horizontal transmission between staphylococcal isolates [29]. Meticillin resistant staphylococci (MRS) are important pathogens in human and veterinary healthcare and are often multi-drug resistant (MDR; resistant to three or more classes of antimicrobial) [30-35], extremely limiting therapeutic options. MRSP clones with a broader resistance spectrum than MRSA or MR-CoNS are increasingly reported in domestic animals throughout Europe, USA and Canada [32,34]. MR-CoNS are associated with infections in humans and animals [31,36-38]. In humans the most prevalent species is MR *S. epidermidis* (MRSE), which may be a reservoir of MR for *S. aureus* [39,40]. In addition, the SCCmec cassette of the major European MRSP clone (ST71-1-t02-II–III) [34] consists of a combination of SCCmec II from MRSE and SCCmec III from MRSA [41].

The prevalence of MRSA and MRSP carriage in healthy humans and dogs in the community is low [11,18,36,42-47]. However, human community-based surveys report a wider range of carriage rates for MR-CoNS (11–50%) [39,48,49]. MR-CoNS have also been isolated from the carriage sites of 13% of healthy dogs [23,50]. The reported prevalence of MRS is higher in animals exposed to veterinary healthcare environments and antimicrobial therapy [47,51-53] suggesting that these are risk factors for colonisation.

Previous studies looking at the commensal staphylococci in dogs have concentrated on CoPS species, particularly MR-CoPS species, the CoNS group or MR-CoNS species [9-11,13,14,17,23,50], but no study has characterised the complete canine commensal staphylococcal population. Moreover, reporting of the antimicrobial treatment history of dogs in these studies have been inconsistent. The aim of this study was to characterise the mucosal staphylococcal population structure and antimicrobial resistance profiles in healthy Labrador retrievers in the UK in the absence of antimicrobial pressure. This will be important in understanding changes in staphylococcal populations and their antimicrobial susceptibility patterns in dogs exposed to antimicrobials and other risk factors.

Methods

Study population

Labrador retriever dogs were recruited for the study from dog shows in the UK between November 2010 and June 2011. One healthy dog was enrolled from each household if the dog had not received topical or systemic antimicrobial therapy, or had not been admitted to a veterinary clinic within the last 12 months. All dog owners gave written informed consent before enrolment in this study and completed a questionnaire regarding potential risk factors for the carriage of antimicrobial resistant bacteria. The University of Liverpool School of Veterinary Science ethics committee approved the study protocol.

Staphylococci

*Specimen collection and bacterial isolation*

One nasal swab and one perineal swab were collected from each dog (Copan Eswab LQ Amies Minitip Nylon Flocked Applicator, Appleton Woods, Birmingham, UK). A sterile swab was either inserted 5 mm into one nostril or rubbed on the skin of the perineum for 3–5 seconds before being placed in Amies transport media, stored at 4°C and processed within 36 hours. Swabs were incubated aerobically overnight at 37°C in nutrient broth with 6.5% sodium chloride. The broth was streaked onto mannitol salt agar (MSA), oxacillin resistance screening agar (ORSA) supplemented with 2 μg/ml of oxacillin and Columbia 5% horse blood agar (CAB), and incubated aerobically overnight at 37°C. Where present, isolates typical of staphylococci were selected from all plates, subcultured onto CAB and incubated aerobically overnight at 37°C. Fresh staphylococcal cultures on CAB were subject...
to Gram stain (Sigma-Aldrich Company Ltd., Gillingham, UK), tested for catalase (Sigma-Aldrich Company Ltd., Gillingham, UK) and free coagulase production (Rabbit plasma, Pro-Lab, Bromborough, UK) according the manufacturer’s instructions and stored at – 80°C in Microbank vials (Pro-Lab, Bromborough, UK). All media were obtained from LabM Ltd, Bury, UK.

**Antimicrobial susceptibility testing**

Disc diffusion testing was performed on all staphylococcal isolates in accordance with the Clinical and Laboratory Standards Institute (CLSI) and the following panel of ten antimicrobial discs were applied: 1 µg oxacillin (OX), 1 µg ciprofloxacin (CIP), 10 µg gentamicin (GM), 10 µg fusidic acid (FA), 30 µg ceftazidime (CFX), 30 µg cefovecin (CVN), 25 µg trimethoprim-sulfamethoxazole (TS), 10 µg tetracycline (Tet), 2 µg clindamycin (CD) and 5 µg vancomycin (Va) [54]. All the discs were purchased from MAST Group Ltd., Liverpool, UK, except for CVN, which were obtained from Oxoid, Basingstoke, UK. Micro-dilution susceptibility testing (Trek Diagnostic Systems, Cleveland, Ohio, USA) was performed on a subset of the CoNS isolates using the same antimicrobial panel, except vancomycin [54]. Interpretation was based on the CLSI guidelines for animal species-specific zone diameter (mm) interpretive standards and minimal inhibitory concentration (MIC; mg/l) breakpoints for veterinary pathogens or human-derived interpretive standards when available. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) zone diameter interpretive standards and MIC breakpoints were used for CIP and FA [55]. The breakpoints used for interpretation of OX resistance was a zone of inhibition of ≤ 17 mm and MIC ≥ 0.5 mg/l for S. pseudintermedius and CoNS, and ≤ 10 mm and MIC ≥ 4 mg/l for S. aureus [56,57]. The breakpoints used for interpretation of resistance to CVN as a zone of inhibition of ≤ 19 mm and MIC ≥ 8 mg/l in accordance with the manufacturer’s recommendations. The reference strain S. aureus ATCC®25923 (LGC Standards, Teddington, UK) was used for quality control for MIC and zone diameter determinations.

**DNA extraction**

Three colonies of each staphylococcal isolate were homogenised in 90 µl of sterile distilled water (SDW) and 10 µl of lysostaphin (1 mg/ml; Sigma-Aldrich Company Ltd., Gillingham, UK) and vortexed for 5 seconds. The suspensions were then incubated at 37°C for 10 minutes and heated at 100°C for 10 minutes before adding 400 µl of SDW. Samples were stored at 4°C.

**Characterisation of antimicrobial resistance genes**

PCR assays were performed to detect the presence of mecA gene (Table 1) in staphylococcal isolates that were phenotypically resistant to oxacillin. All the PCR assays were performed with 0.5 µl of each primer (10 pmol/µl), 1 µl of DNA and 1.1x PCR master mix (ReddyMix™, Thermo Fisher Scientific Inc., Surrey, UK) made up to a total reaction volume of 25 µl. Molecular grade water (Sigma-Aldrich Company Ltd., Gillingham, UK) was used as the negative control in all PCR assays. PCR products were analysed by agarose gel (1.5%) electrophoresis and the DNA fragments were visualised under UV light after ethidium bromide staining.

**Species identification**

**Genotypic species identification**

PCR assays to detect the presence of the nuc genes of S. pseudintermedius, S. aureus and S. schleiferi were performed on all CoPS isolates using Qiagen® Multiplex PCR Mix (Qiagen, Crawley, UK), according to the manufacturer’s instructions with minor modifications. In short, the PCR assays were performed in a reaction volume of 25 µl, consisting of 5 µl of bacterial DNA extract, 12.5 µl of master mix, 2.5 µl of 10x primer mix (2 µM of each primer) and 5 µl of RNase-free water. The cycling conditions consisted of an initial activation step at 95°C for 15 minutes, followed by 30 cycles of 95°C for 30 seconds, 57°C for 90 seconds and 72°C for 60 seconds, and a final extension step at 72°C for 10 minutes (Table 1).

**MALDI-TOF-MS**

All isolates were subjected to matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF-MS) according to the manufacturer’s protocol. Raw spectra were analysed by the MALDI Biotyper 2.0 software programme with default settings (Bruker Daltonics, Bremen, Germany). The extraction method was performed as previously described [58] on overnight colonies grown on CAB at 37°C and all isolates were tested in duplicate. The bacterial test standard (E. coli DH5 alpha, Bruker, Bremen, Germany) was used for calibration before each experiment and included in duplicate on each target plate. The mass peak profiles were matched to the reference database and a score generated based on similarity [59].

**Sequencing**

Two subsets of isolates detected from our group of dogs underwent sequencing following PCR amplification of the tuf gene [59,60]; a control group of CoNS isolates (n = 27) identified by MALDI-TOF-MS and a test group of isolates (n = 52) that had not been identified by MALDI-TOF-MS. Initial PCR assays were performed using HotStarTaq® Master Mix Kit (Qiagen, Crawley, UK) in a 25 µl reaction volume with an initial activation step at 95°C for 15 minutes followed by 35 cycles of 95°C for 30 seconds, 55°C for 30 seconds and 72°C for 30 seconds, with a final
extension step of 72°C for 5 minutes according to the manufacturer's protocol. The resulting amplicons were sequenced using BigDye Terminator version 1.1 cycle sequencing (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol on the ABI3131 genetic analyser at the Department of Microbiology, Royal Liverpool University Hospital. The sequences were aligned using the ABI Sequencing analysis software, with contiguous sequences matched to the GenBank database using the Basic Local Alignment Search Tool (BLAST) [61] and positively identified if there was ≥98% sequence similarity with a reference sequence. S. epidermidis ATCC®12228 was used as the control strain.

Statistical analysis
Data were analysed using SPSS software package (SPSS 20.0 for Mac, SPSS Inc, Chicago, Illinois).
To examine the association between isolation of S. pseudintermedius with each of the 16 different CoNS species Pearson's chi-square was calculated (P<0.003; Bonferroni correction). To examine the association between MR and MDR with potential risk factors (previous antimicrobial therapy or hospitalisation within 12 months of enrolment, health-care or large animal-association by in-contact people or pets) identified from the questionnaires Pearson's chi-square was calculated (P<0.0125; Bonferroni correction). To examine the agreement between antimicrobial susceptibility tests by disc diffusion and MIC a kappa statistic was calculated [62] and an independent t-test was conducted to compare the MIC of oxacillin resistant CoNS isolates that were either positive or negative for the meca gene.

Results
Staphylococci
Specimen collection
Seventy-three Labrador retriever dogs were recruited. Twenty-one dogs were aged between 3 to 12 months, 25 dogs were aged between 12 months to 2 years, and 27 dogs were > 2 years old, with 35 female dogs and 38 male dogs in total.

Bacterial isolation
Staphylococci were isolated from in 72 out of 73 dogs (99%; 95% confidence interval (CI): 99.6-95.8) and from both sample sites in the majority of dogs (78%; 95% CI: 67.3, 86.0). Isolation of staphylococci from the nasal mucosae (16%, 95% CI 9.7, 26.6) or perineum (4%, 95% CI 1.4, 11.4) only occurred in a small number of dogs. If only the nasal mucosae had been sampled, CoPS (all S. pseudintermedius) would not have been detected in seven dogs (10%, 95% CI 4.7, 18.5) and CoNS in six dogs (8%, 95% CI 3.8, 16.8). CoNS were detected in the majority of dogs (95%, 95% CI 86.7, 97.8) either alone (52%, 95% CI 40.8, 63.1) or with CoPS (43%, 95% CI 31.8, 53.9). Detection of CoPS alone was significantly less common (4%, 95% CI 1.4, 11.4). In total, there were 436 staphylococcal isolates; 102 of which were CoPS and 334 were CoNS isolates.

Antimicrobial susceptibility testing by disc diffusion
The overall prevalence of antimicrobial resistance among the isolates detected in this study appeared high, with at least one MDR isolate detected in 34% of dogs. Antimicrobial resistant CoNS isolates were detected in more dogs than antimicrobial resistant CoPS isolates for OX,
GM, FA, CFX, CVN and CD and MDR (Figure 1). At least one OX resistant isolate was detected in 58% dogs (n = 126 oxacillin resistant isolates), but resistance to the other tested β-lactam antimicrobials, CVN (25%) and CFX (29%), was less common. Few CoPS demonstrated antimicrobial resistance; isolates from twelve dogs had Tet resistance (all *S. pseudintermedius*), seven with FA resistance (*S. pseudintermedius* = 5, *S. aureus* = 3); two with TS resistance (both *S. pseudintermedius*); two with CD resistance (*S. pseudintermedius* = 1, *S. aureus* = 1) and two with CIP resistance (both *S. pseudintermedius*). MDR CoPS was detected from only one dog (*S. pseudintermedius* with FA, Tet and CD resistance) (Figure 1).

**MIC compared to disc diffusion testing for antimicrobial resistance**

Micro-dilution susceptibility testing (Trek Diagnostic Systems, Cleveland, Ohio, USA) was performed on 172 CoNS isolates, of which 52 were OX susceptible and 120 were OX resistant by disc diffusion. The OX resistant isolates were further divided into those found to be positive (n = 74) or negative (n = 46) for carriage of the *mecA* gene by PCR. The strength of agreement between antimicrobial resistance detected by MIC and disc diffusion was very good for OX, GM, CVN, Tet and CD resistance, good for CFX and TS resistance and moderate for CIP (*Kappa* = 0.593) and FC resistance (*Kappa* = 0.589). MIC testing identified more isolates as resistant to OX, GM, CFX, CVN and Tet compared to disc diffusion, and disc diffusion identified more isolates as resistant to CIP, FA, TS and CD compared to MIC testing (Table 2).

**Characterisation of antimicrobial resistance genes**

Of the 126 OX resistant CoNS isolates detected by disc diffusion, 75 isolates (60%, 95% CI 51, 68) from 31 dogs (42%, 95% CI 32, 54) were positive for the *mecA* gene (Figure 1). Nine additional oxacillin resistant isolates were detected by MIC and two of these were positive for the *mecA* gene, resulting in two additional dogs with MR-CoNS and one additional dog with phenotypic oxacillin resistant CoNS. There was a significant difference between the MIC of *mecA* positive (M = 3.84, SD = 0.18) and *mecA* negative isolates (M = 0.97, SD = 0.12, *P* < 0.001). In addition the epidemiological breakpoint for OX resistant CoNS isolates with *mecA* gene carriage isolated in this study was consistent with the clinical CLSI breakpoint (≥ 0.5 mg/l) (Figure 2). Eleven different CoNS species (*S. epidermidis, S. warneri, S. sciuri, S. equorum, S. fleurettii,
S. vitulinus, S. saprophyticus, S. haemolyticus, S. lentus, S. succinus and S. pettenkoferi) were found to carry the mecA gene. Among oxacillin resistant CoNS species, St. epidermidis and S. sciuri were more likely to carry the mecA gene than S. saprophyticus, S. equorum, S. vitulinus and S. succinus (Figure 3). MRSE isolates were detected in 18 dogs (25%, 95% CI 14.8, 34.5), meticillin-resistant S. warneri were detected in 7 dogs (10%, 95% CI 2.8, 16.3) and meticillin-resistant S. sciuri were detected in 5 dogs (7%, 95% CI 1.1, 12.6). The remaining species were only isolated from one or two dogs. MDR mecA positive CoNS were detected in 19 dogs (26%, 95% CI 17.3, 37.1). There was no significant association between detection of MR-CoNS or MDR isolates and potential risk factors tested in this study (Pearson’s chi-square; P < 0.0125).

### Species identification

Phenotypic and biochemical methods identified 436 isolates as Staphylococcus species. Using a combination of nuc gene PCR, MALDI-TOF-MS and sequencing of the tuf gene, 399 isolates (92%, 95% CI 88.5, 93.8) were identified to the species level. MALDI-TOF-MS identified 345 isolates to the species level including 264 of 334 CoNS isolates (79%, 95% CI 74.4, 83.1). Amplification and sequencing of the tuf gene identified 33 out of 51 CoNS isolates (65%, 95% CI 51, 76.4) to the species level (n = 11 species; ≥ 98% sequence similarity) and an additional control group (n = 27) of CoNS isolates that had also been identified by MALDI-TOF-MS. There was 100% agreement between the two methods for the identification of the control group. In particular, sequencing of the tuf gene identified all of the S. fleurettii, S. arlettae and S. pettenkoferi isolates, 12 isolates closely related to

| Antimicrobial resistance | MIC | Disc diffusion |  |
|--------------------------|-----|----------------|---|
| Oxacillin (OX)           |     | No             | Yes | Total |
|                          |     | 50             | 10  | 60    |
|                          |     | 2              | 110 | 112   |
|                          |     | 52             | 120 | 172   |
|                           |     |                |     | Kappa = 0.842 |
| Oxacillin mecA positive  |     | No             | Yes | Total |
|                          |     | 115            | 0   | 115   |
|                          |     | 1              | 56  | 57    |
|                          |     | 116            | 56  | 172   |
|                           |     |                |     | Kappa = 0.987 |
| Ciprofloxacin (CIP)      |     | No             | Yes | Total |
|                          |     | 146            | 0   | 157   |
|                          |     | 14             | 15  | 29    |
|                          |     | 160            | 12  | 172   |
|                           |     |                |     | Kappa = 0.593 |
| Gentamicin (GM)          |     | No             | Yes | Total |
|                          |     | 156            | 1   | 157   |
|                          |     | 0              | 15  | 15    |
|                          |     | 156            | 16  | 172   |
|                           |     |                |     | Kappa = 0.965 |
| Fusidic acid (FA)        |     | No             | Yes | Total |
|                          |     | 36             | 5   | 41    |
|                          |     | 25             | 106 | 131   |
|                          |     | 61             | 111 | 172   |
|                           |     |                |     | Kappa = 0.589 |
| Cefalexin (CFX)          |     | No             | Yes | Total |
|                          |     | 117            | 15  | 132   |
|                          |     | 0              | 40  | 40    |
|                          |     | 117            | 55  | 172   |
|                           |     |                |     | Kappa = 0.784 |
| Cefovecin (CVN)          |     | No             | Yes | Total |
|                          |     | 130            | 11  | 141   |
|                          |     | 0              | 31  | 31    |
|                          |     | 130            | 42  | 172   |
|                           |     |                |     | Kappa = 0.810 |
| Tetracycline (T10)       |     | No             | Yes | Total |
|                          |     | 148            | 1   | 149   |
|                          |     | 0              | 23  | 23    |
|                          |     | 148            | 24  | 172   |
|                           |     |                |     | Kappa = 0.975 |

| Antimicrobial resistance | MIC | Disc diffusion |  |
|--------------------------|-----|----------------|---|
| Clindamycin (CD)         |     | No             | Yes | Total |
|                          |     | 148            | 2   | 150   |
|                          |     | 4              | 18  | 22    |
|                          |     | 152            | 20  | 172   |
|                           |     |                |     | Kappa = 0.837 |
S. felis (96% sequence similarity) and an additional 15 isolates to the genus level (Staphylococcus spp. ≥ 98% sequence similarity). PCR amplification of the nuc gene detected all of the S. aureus n = 11 (100%, 95% CI 74.1, 100) and S. pseudintermedius isolates n = 91 (100%, 95% CI 96.0, 100). There was 100% agreement of this assay with MALDI-TOF-MS for the identification of S. aureus isolates, however MALDI-TOF-MS only identified 69 out of 91 S. pseudintermedius isolates.

Overall from the combined results using PCR amplification of the nuc gene, MALDI-TOF-MS and sequencing of the tuf gene we detected S. epidermidis in 52% (95% CI 41, 63) and S. pseudintermedius in 44% (95% CI 33, 55) of the dogs. S. warneri and S. equorum were the

Figure 2 The MIC (µg/ml) data for staphylococcal isolates (n = 172). The isolates consisted of 52 oxacillin susceptible isolates, 46 oxacillin resistant mecA negative isolates and 74 oxacillin resistant mecA positive isolates.
next most common species, isolated from 30% and 27% of dogs respectively, and the remaining staphylococcal species were carried by no more than 15% of the dogs. *S. aureus* was detected in 6 of the dogs, exclusively from the nasal mucosae, and usually with *S. pseudintermedius* (88%, 95% CI 52.9, 97.8). *S. pseudintermedius* was concur-
rently isolated with 16 different CoNS species, although there was no significant association between the presence of *S. pseudintermedius* and any CoNS species (Pearson’s chi-square; *P* < 0.003) (Figure 4 and Table 3).

**Discussion**

This is the first study incorporating MALDI-TOF-MS to successfully characterise commensal staphylococcal pop-
ulations in a group of healthy dogs in the absence of antimicrobial pressure. We isolated staphylococci from 99% of our dogs, with 95% carrying CoNS and 47% carrying CoPS. The relative prevalence of the staphylococci concurs with other published studies in humans [2,3], horses [63-67] and dogs [15,17,68], although the overall staphylococcal prevalence was double that reported for healthy vet visiting dogs [15]. This could be related to the study population and techniques, as we sampled both the nose and the perineum to increase detection of CoPS [12,13,68,69].

We were able to assign 92% of the staphylococcal isolates to 20 different species, including 18 CoNS. This is the first study to demonstrate such diversity in dogs, and carriage of this number of different species has only been previously reported for humans [2,10,12,15,21-26,70]. The

![Figure 4](http://www.biomedcentral.com/1746-6148/10/17) The percentage of dogs (n = 73) carrying each staphylococcal species identified in this study by MALDI-TOF-MS, PCR of the *nuc* gene and sequencing of the *tuf* gene (CoNS grey and CoPS black).
Most common species was \textit{S. epidermidis}, which was detected in 52% of the dogs, mainly from the nasal cavity. This is similar to human reports [71], but apart from one canine study [23], \textit{S. epidermidis} has not been commonly reported in different animal species [67, 72, 73]. \textit{S. pseudintermedius} was the second most common species and the most common CoPS detected, also in agreement with previous reports [9-11, 13]. Unlike \textit{S. epidermidis}, \textit{S. pseudintermedius} was carried equally in the nose and on the perineum, suggesting that this species may have a wider range of mucosal niches. Very few dogs carried \textit{S. aureus} (8%), which is comparable to other studies that reported carriage rates of approximately 7% from healthy vet visiting dogs [12,15]. The majority of the CoNS in our study were human-associated and included \textit{S. epidermidis}, \textit{S. hominis}, \textit{S. haemolyticus}, \textit{S. capitus}, \textit{S. saprophyticus}, \textit{S. warneri}, \textit{S. cohnii}, \textit{S. simulans}, \textit{S. pettenkoferi} and \textit{S. pasteuri}. Human associated CoNS species have previously been isolated from dogs, horses, cows and pigs [23,67,72,74-76]. The other CoNS species isolated from our dogs are reported as indigenous to animals (\textit{S. equorum}, \textit{S. vitulinus}, \textit{S. arlettae S. sciuri}, \textit{S. lentus} and \textit{S. fleurettii}) [2].

We used several methods to identify staphylococcal isolates to species level. Multiplex PCR for the \textit{nuc} gene is an accurate, rapid and cost efficient method to speciate CoPS [77], which identified 100% of our \textit{S. pseudintermedius} (\(n = 91\)) and 100% of our \textit{S. aureus} isolates (\(n = 11\)). Recently MALDI-TOF-MS has been reported as a rapid and reliable method to characterise CoNS, \textit{S. aureus} and \textit{S. intermedicus} group (SIG) strains [59,72,78-80]. MALDI-TOF-MS identified all of our \textit{S. aureus} isolates, 77% of our \textit{S. pseudintermedius} isolates and 79% of our CoNS isolates, identified by phenotypic and biochemical characteristics, to the species level. Similar results for the identification of \textit{S. aureus}, \textit{S. pseudintermedius} and CoNS by

| Staphylococcal species | Number of isolates | Number (%) of positive dogs | Number (%) identified by MALDI-TOF-MS | Number (%) of CoPS identified by \textit{nuc} PCR | Number (%) identified by \textit{tuf} gene sequencing |
|------------------------|--------------------|-----------------------------|--------------------------------------|------------------------------------------|-----------------------------------------------|
| \textit{S. pseudintermedius} | 91                 | 32 (44)                     | 70 (77)                              | 91 (100)                                 | 0                                             |
| \textit{S. aureus}      | 11                 | 6 (8)                       | 11 (100)                             | 11 (100)                                 | 0                                             |
| \textit{S. epidermidis} | 67                 | 38 (52)                     | 64 (96)                              | N/A                                      | 3 (4)                                          |
| \textit{S. warneri}     | 35                 | 22 (30)                     | 35 (100)                             | N/A                                      | 0                                             |
| \textit{S. equorum}     | 39                 | 20 (27)                     | 36 (92)                              | N/A                                      | 3 (8)                                          |
| \textit{S. saprophyticus}| 19                 | 11 (15)                     | 15 (79)                              | N/A                                      | 4 (21)                                         |
| \textit{S. sciuri}      | 27                 | 11 (15)                     | 21 (78)                              | N/A                                      | 6 (22)                                         |
| \textit{S. succinus}    | 19                 | 10 (14)                     | 16 (84)                              | N/A                                      | 3 (16)                                         |
| \textit{S. simulans}    | 15                 | 9 (12)                      | 15 (100)                             | N/A                                      | 0                                             |
| \textit{S. capitus}     | 7                  | 8 (11)                      | 7 (100)                              | N/A                                      | 0                                             |
| \textit{S. pasteuri}    | 8                  | 6 (8)                       | 8 (100)                              | N/A                                      | 0                                             |
| \textit{S. xylosus}     | 17                 | 6 (8)                       | 17 (100)                             | N/A                                      | 0                                             |
| \textit{S. lentus}      | 9                  | 5 (7)                       | 4 (44)                               | N/A                                      | 5 (56)                                         |
| \textit{S. hominis}     | 6                  | 4 (5)                       | 6 (100)                              | N/A                                      | 0                                             |
| \textit{S. cobnii}      | 5                  | 3 (4)                       | 3 (60)                               | N/A                                      | 2 (40)                                         |
| \textit{S. vitulinus}   | 14                 | 3 (4)                       | 13 (93)                              | N/A                                      | 1 (7)                                          |
| \textit{S. haemolyticus}| 4                  | 3 (4)                       | 4 (100)                              | N/A                                      | 0                                             |
| \textit{S. fleurettii}  | 4                  | 2 (3)                       | 0                                    | N/A                                      | 4 (100)                                         |
| \textit{S. arlettae}    | 1                  | 1 (1)                       | 0                                    | N/A                                      | 1 (100)                                         |
| \textit{S. pettenkoferi}| 1                  | 1 (1)                       | 0                                    | N/A                                      | 1 (100)                                         |
| Total ID                | 399\(^a\)         | 72\(^b\)                   | 345\(^c\)                            | 101\(^f\)                                | 33\(^f\)                                       |
| Staphylococcus spp.     | 3                  | N/A                         | N/A                                  | N/A                                      | 3                                             |
| Species related to \textit{S. felis} | 12 | N/A | N/A | N/A | 12 |
| No ID                   | 22                 | 22                          | N/A                                  | 2                                        | 3                                             |
| Total                   | 436\(^a\)         | 73\(^b\)                   | 436\(^b\)                            | 102\(^c\)                                | 51\(^c\)                                       |

Values in the table are expressed as total numbers and percentage in parenthesis where applicable. \(^a\)Total number of isolates in study, \(^b\)total number of dogs in study, \(^c\)total number of isolates tested by each method, \(^d\)total number of isolates with positive identification (ID), \(^e\)number of dogs with staphylococcal detection, \(^f\)number of isolates with positive ID from each method.
MALDI-TOF-MS, in comparison to molecular methods, have been reported [79-81]. The overall performance of MALDI-TOF-MS to speciate the staphylococcal isolates in this study, similar to other reports [80], is likely to be directly related to the database, which at the time of analysis consisted mainly of common human-derived species and only one S. pseudintermedius strain. However species level identification will improve as more highly characterised reference isolates are added to the database. Amplification and sequencing of the tuf gene is regarded as the gold standard to speciate CoNS isolates [59,60]. This method identified 77% of the tested staphylococcal isolates (n = 79) to the species level. The performance of this method in our study may have been affected by the lack of certain-animal derived isolates representing different species in the database. Additionally, we may have improved identification by sequencing a larger region of the tuf gene. We sequenced a previously described 412 base pair region of the tuf gene that was reported to have successfully identified 88% of human-derived staphylococcal strains [60]. However, a more recent publication that sequenced a 660 bp region of the tuf gene, reported 98.9% identification of 186 human and animal-derived staphylococcal strains.

We did not detect any MR-CoPS isolates. Other studies of healthy dogs have similarly reported a low prevalence [15,82,83]. In contrast, 58% of the dogs in our study carried at least one CoNS isolate with phenotypic meticillin resistance and 42% carried a meticillin resistant mecA positive isolate. Other studies have also reported high levels of meticillin resistance among CoNS isolates from humans [31,35,84], horses [23,64-66] and livestock [72,85]. However, the prevalence of MR-CoNS carriage in our study is markedly higher than the levels reported in other community canine studies [15,23,50,74,83]. High community carriage rates of MR-CoNS are of concern for animals and humans, as these organisms may not only be reservoirs of resistance genes for CoPS [39,40,86], but also act as pathogens [31,36-38,87-89]. Cross-transmission is reported to be an important mechanism for dissemination of MRs [49,90], and transmission between dogs and in-contact humans may occur in the community and in veterinary premises [36,83].

Nine different CoNS species carried the mecA gene in our study with MRSE detected in 25% of our dogs. MRSE is the predominant MR-CoNS species in humans both in hospital and community settings [39,48,49], and has been reported in one study investigating nasal carriage of MRs in dogs [23]. Other canine studies have isolated meticillin resistant S. sciuri and meticillin resistant S. warneri [23,74]. Our research found that the majority of the S. sciuri and S. fleurettii isolates were mecA positive, which is consistent with other studies in humans, livestock and horses [35,64,66,67,72].

MDR CoNS (n = 38) were isolated from 34% of dogs in this study. MDR was generally associated with resistance to β-lactams, FA and additional antimicrobials. In particular MDR-MRSE were resistant to at least four antimicrobial classes tested in our study. A similar finding was reported in a study of hospitalised animals, medical equipment and veterinary staff [68]. MDR among CoNS isolates is widely reported [15,49,72,73,91] and may be associated with the carriage of multiple antimicrobial resistance genes on SCCmec cassettes [40]. In contrast, the majority of our commensal CoPS isolates were susceptible to a broad range of antimicrobials (apart from Tet), in line with previous reports for clinical isolates [92-94] and isolates from healthy vet-visiting dogs [15]. There was good to very good agreement between disc and MIC antimicrobial susceptibility testing apart for FC and CIP. These two antimicrobials were the only ones where human breakpoints were applied and emphasises potential species differences in pharmacokinetic and pharmacodynamic data for individual antimicrobials.

The mecA gene was not identified in 40% of the phenotypic oxacillin resistant isolates in this study and may include some isolate duplication due to our sampling methods. Other studies have reported phenotypic meticillin resistance with absence of the mecA gene in staphylococci [95-98]. Our OX-resistant mecA negative isolates may be truly negative for the mecA gene as they were less likely to be resistant to the other antimicrobials tested in this study, including CVN and CFX, and had significantly lower MICs compared to the OX resistant mecA positive isolates. It is possible that they had low-level resistance associated with other mechanisms such as hyperproduction of β-lactamases [99], or production of an oxacillin-specific β-lactamases [100]. There are bovine mastitis CoNS isolates with oxacillin MICs of 0.5 – 1 mg/l that lack the mecA gene [97], and the CLSI guidelines state that ‘oxacillin interpretive criteria may overcall resistance for these CoNS strains’ [57]. In addition, many of the published PCR assays to identify and characterise the mecA gene have been developed for MRSA [101-104] and may therefore lack sensitivity for some CoNS isolates. However, other authors have successfully employed the same methods for mecA detection among CoNS isolates as used in our study [68,98,105]. Nevertheless it is possible that additional PCR assay [106], or latex agglutination for PBP2a [107] may have improved the sensitivity of mecA detection or detected phenotypic mecA-associated resistance in our oxacillin resistant mecA negative isolates.

Our study had some limitations, including the small sample size. Still, these dogs yielded 436 staphylococcal isolates and a high prevalence of resistance was identified among the CoNS isolates even in the absence of antimicrobial exposure. Another weakness was that the study population was limited to one breed (Labrador...
Kennelled dogs have been shown to have higher levels of antimicrobial resistance in faecal *E. coli* than individually owned and non-kennelled dogs [108]. Kennelling was transient in our dogs, but this may have affected the results. Many of the dogs came from multi-dog households but only one dog from each household was sampled to avoid cluster effects.

**Conclusions**

This is the first comprehensive study of commensal staphylococcal populations in a group of healthy dogs. Staphylococci, particularly CoNS, form a normal part of the canine commensal population and were detected from almost all the dogs. The most commonly isolated staphylococcal species in this group of dogs was *S. epidermidis*, although a wide variety of other human- and animal-associated CoNS were found. CoPS were less common, and the major species was *S. pseudintermedius*. Antimicrobial resistance among the CoPS was uncommon, and no MRSP or MRSA were isolated, however the sample size was small. Antimicrobial resistance (including MDR and meticillin resistance) was common among the CoNS isolates, even though this was a community population of healthy dogs in the absence of direct-antimicrobial pressure or veterinary contact. The clinical significance of commensal CoNS and MR-CoNS is unclear, but *S. epidermidis* carries a number of virulence factors and is an increasing cause of nosocomial and community-acquired infections in humans. The possibility of similar infections escalating in companion animals cannot be excluded. In addition, there is potential for cross-species transmission of antimicrobial resistant bacteria and exchange of resistance determinants between bacterial species. In particular, MR- and MDR-CoNS may provide a reservoir of antimicrobial resistance genes that could rapidly spread within bacterial populations under the selection pressure exerted by antimicrobial therapy. Further longitudinal studies in healthy dogs and in dogs receiving antimicrobials are required to assess the population diversity, antimicrobial resistance profiles and persistence of antimicrobial resistant staphylococci in dogs.

**Abbreviations**

CoPs: Coagulase positive staphylococci; CoNS: Coagulase negative staphylococci; MDR: Multidrug resistance; MR: Meticillin resistance; MIC: Minimum inhibitory concentration; MRSA: Meticillin resistant *Staphylococcus aureus*; MRSP: Meticillin resistant staphylococcus *pseudintermedius*; MRSE: Meticillin resistant *Staphylococcus epidermidis*; OX: Oxacillin; CIP: Ciprofloxacin; CFX: Cefalexin; CVN: Cefovecin; TS: Cotrimazole; Tet: Tetracycline; CD: Clindamycin.

**Competing interests**

Vanessa Schmidt, Neil McEwan, Stephen Shaw and Tim Nuttall have received other unrelated funding from Zoetis (previously Pfizer Animal Health UK). The authors declare that there are no financial or non-financial competing interests.

**Authors' contributions**

VS was responsible for sample collection and processing, data analysis and writing the manuscript. NW was responsible for advising on the microbiology methodology used in the study and interpretation of results and contributed to the writing of the manuscript. GP advised on statistical analysis. NM advised on ethical permission and sample collection and contributed to the writing of the manuscript. SS assisted sample collection and contributed to the writing of the manuscript. CEC was responsible for advising on and performing sequencing. SD advised on interpretation of results and contributed to the writing of the manuscript. TN advised on sample collection, interpretation of results and contributed to the writing of the manuscript. All authors were involved in the design of this project and reviewed and approved the final manuscript.

**Acknowledgements**

The authors would like to thank Zoetis (previously Pfizer Animal Health) for funding this project, and Maureen D'Arcy and the North West and Midland Counties Labrador Retriever Clubs for allowing us to obtain samples. We would like to thank Erica Tranfield from Bruker (Liverpool, UK) for training and access to MALDI-TOF-MS Biotyper. We would also like to thank Ruth Ryver and Gill Hutchinson for their technical support, Dorina Timoffe and Andy Wattett for their technical assistance and Andy MacFarlane, Atina Unwin and Camilla Brena for their help in sample collection.

**Author details**

1. Department of Infection Biology, The University of Liverpool, Leahurst Campus, Neston, UK. 2. Department of Epidemiology and Population Health, The University of Liverpool, Leahurst Campus, Neston, UK. 3. Infection and Immunity, Royal Liverpool University Hospital, Liverpool, UK. 4. UK VetDerm, Coalville, UK. 5. The Royal (Dick) School of Veterinary Studies, Easter Bush Campus, University of Edinburgh, Midlothian, UK. 6. The University of Liverpool School of Veterinary Science, Leahurst Campus, Chester High Road, Neston, Wirral CH64 7TE, UK.

Received: 19 April 2013 Accepted: 6 January 2014

**Published: 14 January 2014**

**References**

1. Kloos WE: Natural populations of the genus *Staphylococcus*. Annu Rev Microbiol 1980, 34:559–592.
2. Kloos WE, Bannerman TL: Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev 1994, 7(1):117–140.
3. von Eiff C, Peters G, Heilmann C: Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis 2002, 2(1):677–685.
4. Rich M: Staphylococci in animals: prevalence, identification and antimicrobial susceptibility, with an emphasis on methicillin-resistant *Staphylococcus aureus*. Br J Econ Sci 2005, 62(9):105–108.
5. Devrieze LA, Vancanneyt M, Baele M, Vaneechotte M, De Graef E, Snauwaert C, Cleenwerck I, Dawyndt P, Swings J, Decostere A, et al: *Staphylococcus pseudintermedius* sp. nov., a coagulase-positive species from animals. Int J Syst Evol Microbiol 2005, 55(Pt 1):1569–1573.
6. Mainous AG 3rd, Hueston WJ, Everett CJ, Diaz VA: Nasal carriage of *Staphylococcus aureus* and methicillin-resistant *S. aureus* in the United States, 2001–2002. Ann Fam Med 2006, 4(2):132–137.
7. Huebner J, Goldmann DA: Coagulase-negative staphylococci: role as pathogens. Annu Rev Med 1999, 50:223–236.
8. Mason IS, Mason KV, Lloyd DH: A review of the biology of canine skin with respect to the commensals *Staphylococcus intermedius*, *Demodex canis* and *Malassezia pachydermatis*. Vet Dermatol 1996, 7(3):119–132.
9. Devrieze LA, De Pelsmacker K: The nasal anogenital site as a main carrier site of *Staphylococcus intermedius* and *Streptococcus canis* in dogs. Vet Rec 1987, 121(13):302–303.
10. Griffith GC, Morris DO, Abraham JL, Shoker FS, Rankin SK: Screening for skin carriage of methicillin-resistant coagulase-positive staphylococci and *Staphylococcus schleiferi* in dogs with healthy and inflamed skin. Vet Dermatol 2008, 19(3):142–149.
11. Hanselman BA, Kruth SA, Rousseau J, Weese JS: Coagulase positive staphylococcal colonization of humans and their household pets. Can Vet J 2009, 50(9):954–958.
32. Loeffler A, Williams N, Carter S, McEwan N, Nuttall T: Heterogeneity of Staphylococcus pseudintermedius isolates from atopic and healthy dogs. Vet Dermatol 2010, 21(6):578–585.

33. Rubin JE, Ball KR, Chirino-Trejo M: Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus pseudintermedius isolated from various animals. Can Vet J 2011, 52(4):153–157.

34. Paul NC, Bargman SC, Moodley A, Nielsen SS, Guardabassi L: Staphylococcus pseudintermedius colonisation patterns and strain diversity in healthy dogs: a cross-sectional and longitudinal study. Vet Microbiol 2012, 160(3–4):420–427.

35. Wedley AL: Prevalence of Staphylococcus spp. carriage in dogs. Department of Epidemiology and Population Health, Institute of Infection and Global Health, University of Liverpool, 2012.

36. Pinchbeck LR, Cole LK, Hillier A, Kowalski JJ, Rajala-Schultz PJ, Bannerman TL, York S: Genotypic relatedness of staphylococcal strains isolated from pustules and carriage sites in dogs with superficial bacterial folliculitis. Am J Vet Res 2006, 67(8):1337–1346.

37. Loeffler A, Boag AK, Sung J, Lindsay JA, Guardabassi L, Smith H, Stevens KS, Lloyd DH: Prevalence of methicillin-resistant Staphylococcus aureus among staff and pets in a small animal referral hospital in the UK. J Antimicrob Chemother 2005, 55(6):692–697.

38. Boost MV, O’Donoghue MM, Siu KH: Characterisation of methicillin-resistant Staphylococcus aureus isolates from dogs and their owners. Clin Microbiol Infect 2007, 13(7):731–733.

39. Sakai T, Kikuchi K, Tanaka Y, Takahashi N, Kamata S, Hiramatsu K: Reclassification of phenotypically identified Staphylococcus intermedius strains. J Clin Microbiol 2007, 45(9):2770–2778.

40. Kottler S, Middleton JR, Perry J, Weese JS, Cohn LA: Prevalence of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus carriage in three populations. J Vet Intern Med 2010, 24(1):132–139.

41. Yamashita K, Shimizu A, Kawano J, Uchida E, Haruna A, Igi M: Isolation and characterization of staphylococci from external auditory meatus of dogs with or without otitis externa with special reference to Staphylococcus schleiferi subsp. coagulans isolates. J Vet Med Sci 2005, 67(3):263–268.

42. May ER, Hnilica KA, Frank LA, Jones RD, Bemis DA: Isolation of Staphylococcus schleiferi from healthy dogs and dogs with otitis, pyoderma, or both. J Am Vet Med Assoc 2005, 227(6):928–931.

43. Baggioli FA, Moodley A, Baptiste KE, Jensen VF, Guardabassi L: Occurrence, species distribution, antimicrobial resistance and clonality of methicillin- and erythromycin-resistant staphylococci in the nasal cavity of domestic animals. Vet Microbiol 2007, 121(3–4):307–315.

44. Kania SA, Williamson NL, Frank LA, Jones RD, Bemis DA: Methicillin resistance of staphylococci isolated from the skin of dogs with pyoderma. Am J Vet Res 2004, 65(12):1265–1269.

45. Medleau DA, Long RE, Brown J, Miller WH: Frequency and antimicrobial susceptibility of Staphylococcus species isolated from canine pyoderma. Am J Vet Res 1986, 47(2):229–231.

46. Cox HU, Hoskins JD, Newman SS, Fdil CS, Turmwald GH, Roy AF: Temporal study of staphylococcal species on healthy dogs. Am J Vet Res 1988, 49(6):747–751.

47. Barrosoe J, Guarabassi L: Staphylococcus pseudintermedius in the dog: taxonomy, diagnostics, ecology, epidemiology and pathogenicity. Vet Dermatol 2012, 23(4):253–266. e251-252.

48. Hartman BJ, Tomasz A: Methicillin-resistant, methicillin-susceptible Staphylococcus intermedius in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. Vet Dermatol 2007, 18(6):412–421.

49. Weese JS, van Duijkeren E: Methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius in veterinary medicine. Vet Microbiol 2010, 140(3–4):418–429.

50. Perreten V, Kadelke S, Schlenzke S, Grokland Andersson U, Finn M, Greko C, Moodley A, Kania SA, Frank LA, Bernis DA, et al: Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America: an international multicentre study. J Antimicrob Chemother 2010, 65(11):1145–1154.

51. Garza-Gonzalez E, Morfin-Otero R, Martinez-Vazquez MA, Gonzalez-Diaz E, Gonzalez-Santago D, Rodriguez-Navieja E: Microbiological and molecular characterization of human clinical isolates of Staphylococcus cohoii, Staphylococcus hominis, and Staphylococcus sciuini. Scand J Infect Dis 2011, 43(11–12):930–936.

52. van Duijkeren E, Kamphuis M, van der Mijt IC, Laarhoven LM, Duin B, Wagenaar JA, Houwers DJ: Transmission of methicillin-resistant Staphylococcus pseudintermedius between infected dogs and cats and contact pets, humans and the environment in households and veterinary clinics. Vet Microbiol 2011, 150(3–4):335–343.

53. Hauschild T, Wojcik A: Species distribution and properties of staphylococci from canine dermatitis. Res Vet Sci 2007, 82(1):1–6.

54. Kern A, Perreten V: Clinical and molecular features of methicillin-resistant, coagulase-negative staphylococci of pets and horses. J Antimicrob Chemother 2013, 68(8):1256–1266.

55. Bartfai F, Ruppe E, Hernando O, Debeaux D, Francois P, Felix B, Desprez A, Maiga A, Woerther PL, Gaillard K, et al: Methicillin-resistant coagulase-negative staphylococci in the community: high homology of SCCmec IVa between Staphylococcus epidermidis and major clones of methicillin-resistant Staphylococcus aureus. J Infect Dis 2010, 202(2):270–281.

56. Smyth DS, Wong A, Robinson DA: Cross-species spread of SCCmec IV subtypes in staphylococci. Infect Genet Evol 2011, 11(6):446–453.

57. Dieroux S, Rossano A, Perreten V: Characterization of new staphylococcal cassette chromosome mec (SCCmec) and toxin-isoasemser genes in fluoroquinolone- and methicillin-resistant Staphylococcus pseudintermedius. J Clin Microbiol 2008, 46(1):1818–1823.

58. Abduu L, Blair I, Fraise A, Cheng KK: Methicillin-resistant Staphylococcus aureus (MRSA): a community-based prevalence survey. Epidemiol Infect 2001, 126:3351–3356.

59. Shopsin B, Mathema B, Martinez J, Ha E, Campo ML, Fierman A, Krasinski K, Kornblum J, Alcaubes P, Waddington M, et al: Prevalence of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in elderly people living in their own homes: implications for treatment, screening and surveillance in the UK. J Hosp Infect 2004, 57(3):258–262.

60. Sa-Leao R, Sanches I, Couto I, Alves OR, de Lencastre H: Low prevalence of methicillin-resistant strains among Staphylococcus aureus colonizing young and healthy members of the community in Portugal. Microb Drug Resist 2001, 7(3):237–245.

61. Zanelli G, Sansoni A, Zanchi A, Cresti S, Pollini S, Rossolini GM, Cellesi C: Staphylococcus aureus nasal carriage in the community: a survey from central Italy. Epidemiol Infect 2002, 129(2):417–420.

62. Loeffler A, Pfeiffer DU, Lindsay JA, Magalhaes RJ, Lloyd DH: Prevalence of and risk factors for MRSA carriage in companion animals: a survey of dogs, cats and horses. Epidemiol Infect 2009, 137(1):10–10.

63. Debeaux D, Barbier F, Angabault C, Benmahdi L, Ruppe E, Felix B, Gaillard K, Djoussou F, Epelboin L, Dupont C, et al: Evolution of nasal carriage of methicillin-resistant coagulase-negative staphylococci in a remote population. Antimicrob Agents Chemother 2012, 56(3):315–323.

64. Silva FR, Mattos EM, Coimbra MV, Ferreira-Cavalo BT, Figueredo AM: Isolation and molecular characterization of methicillin-resistant coagulase-negative staphylococci from nasal flora of healthy humans at three community institutions in Rio de Janeiro City. Epidemiol Infect 2001, 127(1):57–62.

65. Vengust M, Anderson ME, Rousseau J, Weese JS: Methicillin-resistant staphylococcal colonization in clinically normal dogs and horses in the community. Lett Appl Microbiol 2006, 43(5):602–606.

66. Niënhoorn U, Kadelke C, Chaberny IF, Veepohlt J, Gerlich GF, Kreienbrock L, Schwarz S, Simon D, Nolte J: Methicillin-resistant Staphylococcus
pseudintermedius among dogs admitted to a small animal hospital. Vet Microbiol 2011, 150(1–2):191–197.

52. Bergstrom A, Gustafsson C, Leander M, Fredriksson M, Gronlund U, Trowald-Wig W: Occurrence of methicillin-resistant staphylococci in surgically treated dogs and the environment in a Swedish animal hospital. J Small Anim Pract 2012, 53(7):404–410.

53. Huerta B, Maldonado A, Gineli PJ, Tarradas C, Gomez-Gascon I, Astorga RJ, Luque I: Risk factors associated with the antimicrobial resistance of staphylococci in canine pyoderma. Vet Microbiol 2011, 150(3–4):302–308.

54. CLSI (Ed): Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved Standard—Third Edition. CLSI document M31-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.

55. EUCAST: Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1. 2013. http://www.eucast.org.

56. Bemis DA, Jones RD, Frank LA, Kania SA: Evaluation of susceptibility test breakpoints used to predict mecA-mediated resistance in Staphylococcus pseudintermedius isolated from dogs. J Vet Diagn Invest 2009, 21(1):53–58.

57. CLSI (Ed): Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; Approved standard–Fourth Edition. CLSI document VET01-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.

58. Alatoom AA, Cunningham SA, Ihde SM, Mandrekar J, Patel R: Measurement of observer agreement for categorical data. J Clin Microbiol 1977, 34(3):489–490.

59. Carpaij N, Willems RJ, Bonten MJ, Fluit AC: Identification of a variety of Staphylococcus species by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2010, 48(3):791–796.

60. Heikens E, Fleer A, Paauw A, Florijn A, Fluit AC: The prevalence of methicillin-resistant staphylococci in healthy horses in the Netherlands. Vet Microbiol 2006, 113(1–2):131–136.

61. Moodley A, Guardabassi L: Genetic and phenotypic methods for species-level identification of clinical isolates of coagulate-negative staphylococci. J Clin Microbiol 2005, 43(5):2286–2290.

62. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol 1990, 215(3):403–410.

63. Landis JR, Koch GG: Measurement of observer agreement for categorical data. Biometrics 1977, 33(1):159–174.

64. Yasuda R, Kawanou J, Onda H, Takagi M, Shimizu A, Anzai T: Methicillin-resistant coagulate-negative staphylococci isolated from healthy horses in Japan. Am J Vet Res 2001, 61(11):1451–1455.

65. Busscher JF, van Duijkeren E, Sooten van Oldrutenhoef-Oosterbaan MM: The prevalence of methicillin-resistant staphylococci in healthy horses in the Netherlands. Vet Microbiol 2006, 113(1–2):131–136.

66. Moodley A, Guardabassi L: Clonal spread of coagulate-negative staphylococci among horses, personnel and environmental sites at equine facilities. Vet Microbiol 2009, 137(3–4):397–401.

67. De Martino L, Lucido M, Mallardo K, Facello B, Mallardo M, Iovane G, Pagnini U, Tufano MA, Catalanotti P: Identification and methicillin resistance of Staphylococcus pseudintermedius isolated from healthy dogs and horse personnel in Italy. J Med Microbiol 2010, 59(Pt 7):787–790.

68. Decristophoris P, Fasola A, Benagli C, Tonolla M, Petroni O: Identification of Staphylococcus intermedius Group by MALDI-TOF MS. J Vet Appl Microbiol 2011, 34(1):45–51.

69. Widerstrom M, Wistrom J, Spodtset A, Monsen T: Colagulate-negative staphylococci isolated from the molecular epidemiology and clinical presentation, with a focus on Staphylococcus epidermidis and Staphylococcus saprophyticus. Eur J Clin Microbiol Infect Dis 2012, 31(7–8).

70. Rogers KL, Fey RD, Rupp ME: Coagulate-negative staphylococcal infections. Infect Dis Clin North Am 2009, 23(1):73–98.

71. Huber H, Ziegler D, Pfuger V, Vogel G, Zwerfel C, Stephan R: Prevalence and characteristics of methicillin-resistant coagulate-negative staphylococci from livestock, chicken carcasses, bulk tank milk, minced meat, and contact persons. BMC Vet Res 2011, 7:6.

72. Garbacz K, Zamowska S, Piekowicz L, Haras K: Staphylococci isolated from carriage sites and infected sites of dogs as a reservoir of multidrug resistance and methicillin resistance. Curr Microbiol 2013, 66(2):169–173.

73. Malik S, Coombs GW, O’Brien FG, Feng H, Barton MD: Molecular typing of methicillin-resistant staphylococci isolated from cats and dogs. J Antimicrob Chemother 2006, 58(2):428–431.

74. Gielisse BE, Headrick SL, Boonyanya S, Oliver SP: Prevalence and persistence of coagulate-negative Staphylococcus species in three dairy research herds. Vet Microbiol 2009, 134(1–2):65–72.

75. Tuliński P, Fluit AC, Wagenaar JA, Mevius D, van de Vijver L, Duin B: Methicillin-resistant coagulate-negative staphylococci on pig farms as a reservoir of heterogeneous staphylococcal cassette chromosome mec elements. Appl Environ Microbiol 2012, 78(2):299–304.

76. Sasaki T, Tsukahakita S, Tanaka Y, Sakusabe A, Ohtsuka M, Hirotski S, Kawatami T, Fukuta T, Hiramatsu K: Multiplex-PCR method for species identification of coagulate-positive staphylococci. J Clin Microbiol 2010, 48(3):765–769.

77. Dubois D, Leyeuxene D, Chacornac JP, Kowstrewa M, Schmit PD, Talon R, Bonnet R, Delmas J: Identification of methicillin-resistant S. pseudintermedius by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2010, 48(3):941–945.

78. Szabados W, Woloszyn J, Richter C, Kaise M, Gatenmann S: Identification of molecularly defined Staphylococcus aureus strains using matrix-assisted laser desorption ionization-time of flight mass spectrometry and the Biotyping 2.0 database. J Med Microbiol 2010, 59(Pt 7):787–790.

79. Decristophoris P, Fasola A, Benagli C, Tonolla M, Petrini O: Identification of Staphylococcus intermedius Group by MALDI-TOF MS. J Vet Appl Microbiol 2011, 34(1):45–51.

80. Bergeron M, Daouwalder O, Gouy M, Freydiere AM, Bes M, Meugnier H, Benito Y, ETienne J, Lina G, Vandenesch F, et al: Species identification of staphylococci by amplification and sequencing of the tuf gene compared to the gap gene and by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2010, 48(3):941–945.

81. Windahl U, Reimegard E, Holst BS, Egenvall A, Fernstrom L, Fredriksson M, Trowald-Wigh G, Andersson UG: The prevalence of methicillin-resistant staphylococci in healthy horses among dogs admitted to a small animal hospital. Vet Microbiol 2010, 138(1–2):45–51.

82. Tsubakishita S, Kuwahara-Arai K, Sasaki T, Hiramatsu K: Genetic and phenotypic molecular evolution of the determinant of methicillin resistance in staphylococci. Antimicrob Agents Chemother 2010, 54(10):4352–4359.

83. Duval X, Selton-Suty C, Alla F, Salvador-Mazeng M, Bernard Y, Weber M, Lacassin F, Nazezrylas P, Chidic C, Hoen B, et al: Endocarditis in patients with a permanent pacemaker: a 1-year epidemiological survey on infective endocarditis due to valvular and/or pacemaker infection. Clin Infect Dis 2004, 39(1):68–74.

84. Morgan E, Masters S, Berendt AR, McLardy-Smith P, Byeon I, Atkins BL: Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthetic retention. J Infect 2007, 55(1):1–7.

85. Pette A, Verschraegen G: Role of coagulate-negative staphylococci in human disease. Vet Microbiol 2009, 134(1–2):45–54.

86. Ciminiello JP, Wu F, Della-Latta P, Nesin M, Larson E: Emergence of resistant staphylococci on the hands of new graduate nurses. Infect Control Hosp Epidemiol 2004, 25(5):431–435.

87. Wang J, Kozinetz CA, Peterson DT, Solberg EM, Ebert EC, Wenzel RP, Edmond MB: Nasocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309–317.

88. Lloyd DH, Lampert AI, Feneey C: Sensitivity to antibiotics amongst cutaneous and mucosal isolates of canine pathogenic staphylococci in the UK, 1980–96. Vet Dermatol 1996, 7:171–175.
93. Kruse H, Hofshagen M, Thoresen SI, Bredal WP, Vollset J, Soli NE: The antimicrobial susceptibility of Staphylococcus species isolated from canine dermatitis. Vet Res Commun 1996, 20(3):205–214.
94. Hoekstra KA, Paulton RJ: Clinical prevalence and antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus intermedius in dogs. J Appl Microbiol 2002, 93(3):406–413.
95. Suzuki E, Hiramatsu K, Yokota T: Survey of methicillin-resistant clinical strains of coagulase-negative staphylococci for mecA gene distribution. Antimicrob Agents Chemother 1992, 36(2):429–434.
96. Bignardi GE, Woodford N, Chapman A, Johnson AP, Speller DC: Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005, 43(10):5026–5033.
97. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM: Identification and characterization of methicillin-resistant coagulase-negative staphylococci from bovine mastitis. J Antimicrob Chemother 2010, 65(8):1576–1582.
98. Eckholm NG, Outebringe CA, White SD, Sykes JE: Prevalence of oxacillin- and multidrug-resistant staphylococci in clinical samples from dogs: 1,772 samples (2001–2005). J Am Vet Med Assoc 2007, 230(2):221–227.
99. Mehrotra M, Wang G, Johnson WM: Rapid detection of methicillin-resistant Staphylococcus aureus enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. J Clin Microbiol 2000, 38(3):1032–1035.
100. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, Hiramatsu K: Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrob Agents Chemother 2007, 51(1):264–274.
101. Jones RD, Kania SA, Rohrbach BW, Frank LA, Bemis DA: Oxacillin and multidrug resistant Staphylococcus aureus isolates with borderline or low-level methicillin resistance. J Med Microbiol 1983, 16(4):391–399.
102. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM: Novel intergenic deletion–insertion–deletion genotyping assay for Staphylococcus aureus strains. J Clin Microbiol 2001, 39(2):727–732.
103. Ruppe E, Hiramatsu K, Yokota T: Survey of methicillin-resistant clinical strains of coagulase-negative staphylococci for mecA gene distribution. Antimicrob Agents Chemother 1992, 36(2):429–434.
104. Bignard GE, Woodford N, Chapman A, Johnson AP, Speller DC: Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005, 43(10):5026–5033.
105. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, Hiramatsu K: Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrob Agents Chemother 2007, 51(1):264–274.
106. Francois P, Pittet D, Bento M, Pepey B, Vaudaux P, Lew D, Schrenzel J: Rapid detection of methicillin-resistant Staphylococcus aureus directly from sterile or nonsterile clinical samples by a new molecular assay. J Clin Microbiol 2003, 41(3):254–260.
107. Ruppe E, Barbier F, Merli Y, Maiga A, Cojocaru R, Benkhalfat M, Benchouk S, Hassaine H, Maiga I, Diallo A, et al: Diversity of staphylococcal cassette chromosome mec structures in methicillin-resistant Staphylococcus epidermidis and Staphylococcus haemolyticus strains among outpatients from four countries. Antimicrob Agents Chemother 2009, 53(2):442–449.
108. Murakami K, Minamide W, Wada K, Nakamura E, Teraoka H, Watanabe S: Detection of methicillin-resistant Staphylococcus aureus by polymerase chain reaction. Rinsho Byori 1991, 39(12):1325–1330.
109. Baddour MM, AbuElKheir WM, Fatani AJ: Comparison of mecA polymere chain reaction with phenotypic methods for the detection of methicillin-resistant Staphylococcus aureus. Curr Microbiol 2007, 55(6):473–479.